---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020349"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:36:57.769860+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics raises $14M in registered direct offering with warrants

## Summary
- Total gross proceeds of $14M from sale of 188,383 shares and pre-funded warrants for up to 3,811,617 shares.
- Combined offering price: $3.50 per share + accompanying warrant; $3.499 per pre-funded warrant + accompanying warrant.
- Warrants exercisable at $4.20 per share; option warrants to purchase up to 4,000,000 additional shares.
- Placement agent Rodman & Renshaw receives a 6.0% cash fee on gross proceeds.
- Closing expected on first Trading Day after March 3, 2025.

## SEC filing metadata
- accession: 0001104659-25-020349
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/0001104659-25-020349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925020349/tm258193-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020349
- JSON: https://secwatch.observer/filing/0001104659-25-020349.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.